The results of this study demonstrated that treating mice rendered colitic by administration of oxazolone and DSS with BAR501, a GPBAR1 agonist, protected against the development of colitis, attenuated the signs and symptoms of colitis and reversed the immune dysfunction that typically occurs in this model, although upregulated the expression of Ace2 in the colon. This evidence concerns the gene GPBAR1 and colitis.